GlassScriptPhysician profile
Michael J Zachek
NPI 1457357865
$34,426.90
in general payments reported to CMS, 2019-2025
31 companies · $1,256 in 2025
The $1,256 reported for 2025 was more than what 75% of Sleep Medicine (Internal Medicine) providers received nationally (typical 2025 total: $447).
See the full distribution for Sleep Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $771 · 2020: $6,667 · 2021: $15K · 2022: $8,895 · 2023: $581 · 2024: $1,199 · 2025: $1,256.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,578 · Education: $258 · Consulting Fee: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,578.11 |
| Education | $257.88 |
| Consulting Fee | $200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $30,310.69 | 2020-2025 | Wakix |
| Jazz Pharmaceuticals INC. | $950.29 | 2019-2025 | |
| Avadel Cns Pharmaceuticals, LLC | $704.50 | 2023-2025 | Lumryz |
| Axsome Therapeutics, INC. | $455.38 | 2023-2025 | Sunosi |
| Inspire Medical Systems, INC. | $312.89 | 2021-2025 | Inspire |
| Astrazeneca Pharmaceuticals LP | $254.10 | 2019-2024 | Tezspire |
| Idorsia Pharmaceuticals US INC | $224.81 | 2023-2025 | Quviviq, Quviviq |
| Glaxosmithkline, LLC. | $183.50 | 2019-2023 | Trelegy Ellipta |
| Philips North America LLC | $154.22 | 2019-2022 | |
| Insmed, INC. | $137.08 | 2020-2021 | |
| Eisai INC. | $125.00 | 2019 | |
| Fisher & Paykel Healthcare INC | $108.94 | 2023-2025 | Fisher & Paykel Healthcare |
| Novartis Pharmaceuticals Corporation | $54.45 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.75 | 2019-2020 | |
| Ucb, INC. | $51.52 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $39.03 | 2019 | |
| 3b Medical, INC. | $36.86 | 2023-2025 | Luna |
| Amarin Pharma, INC. | $34.09 | 2019 | |
| Hikma Pharmaceuticals USA | $31.79 | 2025 | Ryaltris |
| Lilly USA, LLC | $27.60 | 2025 | Zepbound |
| Resmed Corp | $27.28 | 2025 | |
| Baxter Healthcare | $20.73 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Csl Behring | $20.61 | 2019 | |
| Sunovion Pharmaceuticals INC. | $16.23 | 2019 | |
| Itamar Medical INC | $14.82 | 2022 | |
| Arbor Pharmaceuticals, INC. | $14.00 | 2021 | |
| Mylan Specialty L.P. | $13.77 | 2022 | |
| Merck Sharp & Dohme LLC | $13.64 | 2021 | |
| Astellas Pharma US INC | $13.28 | 2019 | |
| Advanced Respiratory, INC | $11.69 | 2020 | |
| Melinta Therapeutics, LLC | $11.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Zachek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.